Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Licensing Agreement with Cannabis Edibles Infusion Manufacturer
- Lexaria enters agreement with Biolog for Lexaria’s DehydraTECH™ technology in return for royalties on sales revenue and licensing fees
- Biolog has exclusive rights to use the Lexaria technology for its particular applications for five years
- Lexaria is the only company worldwide with patent issued for oral delivery CBD and all other non-psychoactive cannabinoids
Based in Kelowna, British Columbia, Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) announced on February 27, 2018, its entry into a technology licensing agreement with Biolog, Inc. for the provision of Lexaria’s patented DehydraTECH™ technology (http://nnw.fm/sVSQ4). Lexaria’s proprietary technology will be used in the formulation of a unique range of next-generation Biolog food and beverage cannabis infusion products to be sold in the United States.
California-focused Biolog (a Utah company, not to be confused with a California cell phenotyping company of the same name) has its own patented technologies for a unique line of dissolvable infusion products designed for precise per-unit ingredient dosing and ease of use. The company plans to integrate Lexaria’s DehydraTECH™ delivery technology in products of this type. Biolog’s new product range will include hemp-based, cannabidiol (CBD)-infused products and vitamins for distribution in those states where such products are legalized. Lexaria’s patented technology will offer these products superior bioabsorption, fast action and better taste.
“The versatility of Lexaria’s DehyrdaTECH (TM) technology is witnessed through its adoption to deliver vitamins in a nationally-available consumer product, or cannabinoids in many U.S. states,” Lexaria CEO Chris Bunka said in a news release. “Biolog’s products are a unique and novel method to deliver precisely measured amounts of active ingredients thoroughly infused into foods and beverages of virtually all kinds and we welcome Biolog to our growing family of technology innovators.”
Biolog has secured five-year exclusive rights to use Lexaria’s DehyrdaTECH™ technology for its particular applications within the U.S. In exchange, Lexaria will receive a royalty on revenue generated from sales of these products. CEO of Biolog Craig Machado expressed the company’s excitement in offering the market ‘Powered by Lexaria’ products. “We plan to provide more information about our upcoming products, which will allow processors and consumers to turn almost any food or beverage into a cannabis edible in the near future, as we get closer to formal product launch,” Machado added in the release.
Lexaria has been awarded patents in Australia and the United States for its DehyrdaTECH™ technology and has patents pending in over 40 other countries around the world. It has the distinction of being the only company in the world with a patent for the oral delivery of CBD and all other non-psychoactive cannabinoids. This proven technology enhances the taste, smell, bioabsorption, speed of action and bioavailability of active ingredients in ingestible products. It eliminates the need for sugars and sweeteners used in other technologies to mask bitter tastes and unpleasant odors. Bioabsorption of active compounds and cannabinoids is increased by up to 10 times, while the effects are registered within a fraction of the time taken with other delivery technologies.
DehyrdaTECH™ technology can either reduce the cannabinoid per serving unit cost or produce stronger effects in cases where serving levels are regulated. Consumers gain significant benefits from the enhanced taste of edibles and the speed of action. The technology can be applied to the manufacture of foods, liquids, emulsions, capsules and tablets. Lexaria has a range of products for testing and sales, including protein energy bars, CBD tablets and a high-absorption hemp oil capsule called TurboCBD.
For more information, visit the company’s website at www.LexariaEnergy.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria enters agreement with Biolog for Lexaria’s DehydraTECH™ technology in return for royalties on sales revenue and licensing fees
- Biolog has exclusive rights to use the Lexaria technology for its particular applications for five years
- Lexaria is the only company worldwide with patent issued for oral delivery CBD and all other non-psychoactive cannabinoids
Based in Kelowna, British Columbia, Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) announced on February 27, 2018, its entry into a technology licensing agreement with Biolog, Inc. for the provision of Lexaria’s patented DehydraTECH™ technology (http://nnw.fm/sVSQ4). Lexaria’s proprietary technology will be used in the formulation of a unique range of next-generation Biolog food and beverage cannabis infusion products to be sold in the United States.
California-focused Biolog (a Utah company, not to be confused with a California cell phenotyping company of the same name) has its own patented technologies for a unique line of dissolvable infusion products designed for precise per-unit ingredient dosing and ease of use. The company plans to integrate Lexaria’s DehydraTECH™ delivery technology in products of this type. Biolog’s new product range will include hemp-based, cannabidiol (CBD)-infused products and vitamins for distribution in those states where such products are legalized. Lexaria’s patented technology will offer these products superior bioabsorption, fast action and better taste.
“The versatility of Lexaria’s DehyrdaTECH (TM) technology is witnessed through its adoption to deliver vitamins in a nationally-available consumer product, or cannabinoids in many U.S. states,” Lexaria CEO Chris Bunka said in a news release. “Biolog’s products are a unique and novel method to deliver precisely measured amounts of active ingredients thoroughly infused into foods and beverages of virtually all kinds and we welcome Biolog to our growing family of technology innovators.”
Biolog has secured five-year exclusive rights to use Lexaria’s DehyrdaTECH™ technology for its particular applications within the U.S. In exchange, Lexaria will receive a royalty on revenue generated from sales of these products. CEO of Biolog Craig Machado expressed the company’s excitement in offering the market ‘Powered by Lexaria’ products. “We plan to provide more information about our upcoming products, which will allow processors and consumers to turn almost any food or beverage into a cannabis edible in the near future, as we get closer to formal product launch,” Machado added in the release.
Lexaria has been awarded patents in Australia and the United States for its DehyrdaTECH™ technology and has patents pending in over 40 other countries around the world. It has the distinction of being the only company in the world with a patent for the oral delivery of CBD and all other non-psychoactive cannabinoids. This proven technology enhances the taste, smell, bioabsorption, speed of action and bioavailability of active ingredients in ingestible products. It eliminates the need for sugars and sweeteners used in other technologies to mask bitter tastes and unpleasant odors. Bioabsorption of active compounds and cannabinoids is increased by up to 10 times, while the effects are registered within a fraction of the time taken with other delivery technologies.
DehyrdaTECH™ technology can either reduce the cannabinoid per serving unit cost or produce stronger effects in cases where serving levels are regulated. Consumers gain significant benefits from the enhanced taste of edibles and the speed of action. The technology can be applied to the manufacture of foods, liquids, emulsions, capsules and tablets. Lexaria has a range of products for testing and sales, including protein energy bars, CBD tablets and a high-absorption hemp oil capsule called TurboCBD.
For more information, visit the company’s website at www.LexariaEnergy.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
